Samsung Display and Ferrari Sign MOU to Bring Samsung OLED to Next-Generation Models
11.4.2023 12:00:00 EEST | Business Wire | Press release
Samsung Display announced today that the company has signed a memorandum of understanding (MOU) with Ferrari at Samsung Display’s Asan campus in Korea to develop a display solution for implementation in Ferrari’s next-generation models. JS Choi, President and CEO of Samsung Display, and Benedetto Vigna, CEO of Ferrari, attended the signing ceremony.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230411005025/en/
Samsung Display CEO JS Choi (right) and Ferrari CEO Benedetto Vigna (left) shake hands after a Memorandum of Understanding signing ceremony held at Samsung Display's Asan campus in Korea. (Photo: Business Wire)
With this MOU, Samsung Display will develop an innovative automotive display solution befitting a luxury supercar brand with world-leading OLED technology in order to support the seamless digital transformation of Ferrari.
Over the past decade, Samsung Display has been leading the technology transition in the premium smartphone market from LCD to OLED. As an industry leader in the premium display market and pioneer of revolutionary OLED technology since 2007, Samsung Display is now actively targeting the automotive display market which is an important technology and business platform.
At CES 2023, Samsung Display unveiled its New Digital Cockpit with a 34-inch slim bezel display and bendable technology that creates 700R curvature during the driving mode.
The lightweight, slim structure and the thin bezel of OLED panels allow for high levels of design freedom and its true black and high-contrast capabilities satisfy the design needs of leading automakers. Moreover, OLED’s low power consumption offers even greater benefits, since every watt saved improves the car’s efficiency and sustainability.
“In the luxury sector, elevating the client’s experience is key,” said Benedetto Vigna, CEO of Ferrari. “Through this strategic partnership with Samsung Display for the dedicated development of bespoke OLED technology display solutions, we will make a significant step forwards in the digital environment of our next-generation models.”
“Based on our extensive expertise in OLED technology, we are poised to introduce cutting-edge display solutions that meet the Ferrari standard,” said JS Choi, President and CEO of Samsung Display. “We are certain that our collaboration with Ferrari will provide an exciting opportunity to apply our strengths to the supercar field and reinforce our position in the automotive OLED market, enabling us to reach ever new heights.”
###
About Samsung Display
Samsung Display Co., Ltd. is an industry leader in providing cutting-edge display solutions around the world. The company diversifies its display markets to not only smartphones, TVs, laptops, and monitors but also smartwatches, VR, game consoles, and automotive applications. Furthermore, it has close partnerships with a variety of global manufacturers. Headquartered in South Korea, with a range of large-scale facilities, Samsung Display has production plants in China, Vietnam, and India, and operates sales offices in nine countries worldwide. Known for its innovation, Samsung Display is leading the foldable display market, enabling the world’s first mass-production of OLED, endeavoring to develop next-generation technology such as high image quality QD (Quantum Dot)-OLED, slidable and stretchable panels to provide extraordinary experiences and endless possibilities for consumers.
Samsung Display has been prioritizing environmental and social values in the entire process of product manufacturing. The company will further evolve into a sustainable organization dedicated to environmentally-sound products that contribute to the betterment of humanity.
For more information, please visit www.samsungdisplay.com or http://global.samsungdisplay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005025/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: sseg.comm@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom